Autolus Therapeutics (NASDAQ:AUTL) Stock Price Up 16.1% on Strong Earnings

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL)’s share price rose 16.1% during trading on Monday after the company announced better than expected quarterly earnings. The company traded as high as $1.8350 and last traded at $1.8920. Approximately 873,891 shares changed hands during mid-day trading, a decline of 49% from the average daily volume of 1,728,245 shares. The stock had previously closed at $1.63.

The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $26.22 million during the quarter, compared to analyst estimates of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%.

Analysts Set New Price Targets

AUTL has been the subject of a number of research analyst reports. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Weiss Ratings lowered shares of Autolus Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 14th. HC Wainwright upped their price target on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, May 14th. Truist Financial raised shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.75.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Mak Capital One LLC lifted its stake in Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after purchasing an additional 3,987,727 shares during the last quarter. Armistice Capital LLC lifted its stake in Autolus Therapeutics by 12.2% during the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after purchasing an additional 1,900,000 shares during the last quarter. Schroder Investment Management Group lifted its stake in Autolus Therapeutics by 12.5% during the fourth quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock valued at $18,694,000 after purchasing an additional 1,056,092 shares during the last quarter. Bank of America Corp DE lifted its stake in Autolus Therapeutics by 108.1% during the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after purchasing an additional 1,054,458 shares during the last quarter. Finally, Atle Fund Management AB lifted its stake in Autolus Therapeutics by 5.8% during the third quarter. Atle Fund Management AB now owns 1,169,634 shares of the company’s stock valued at $1,907,000 after purchasing an additional 64,173 shares during the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Down 9.4%

The firm has a market capitalization of $433.81 million, a price-to-earnings ratio of -1.50 and a beta of 1.93. The firm’s 50 day moving average is $1.49 and its 200 day moving average is $1.52.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.